Show simple item record

dc.creatorForsdahl, Guro
dc.creatorJančić-Stojanović, Biljana
dc.creatorAnđelković, Marija
dc.creatorDikić, Nenad
dc.creatorGeisendorfer, Tomas
dc.creatorJeitler, Veronika
dc.creatorGmeiner, Gunter
dc.date.accessioned2019-09-02T12:03:24Z
dc.date.available2019-09-02T12:03:24Z
dc.date.issued2018
dc.identifier.issn0731-7085
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/3044
dc.description.abstractMeldonium is a drug exhibiting cardioprotective and anti-ischemic effects. Due to its potential performance-enhancing benefit in sports, meldonium was added to the World Anti-Doping Agency list of prohibited substances in 2016. Since then, a high number of adverse analytical findings reported on meldonium has questioned meldonium's detection time in urine. Hence, the objective of the current study was to characterize the pharmacokinetic urinary excretion pattern of meldonium when administered as multiple intravenous injections. Three injections of 250 mg meldonium were given over a time period of five days to six healthy volunteers and urine samples were collected for eight months after the last injection of the drug. For the quantification of meldonium in urine, a liquid chromatography-tandem mass spectrometry method was fully validated according to the World Anti-Doping Agency guidelines in terms of specificity, matrix interferences, intra- and inter-day precision, accuracy, carry-over, robustness, linearity, limit of detection, and limit of quantification. The assay was successfully applied to the pharmacokinetic study. A three-compartment model was found to best describe the pharmacokinetics of meldonium with average alpha, beta, and gamma half-lives of 1.4 h, 9.4 h, and 655 h, respectively. The detection time in urine varied between 94 and 162 days.en
dc.publisherElsevier Science BV, Amsterdam
dc.relationAustrian Ministry of Defence and Sports
dc.rightsrestrictedAccess
dc.sourceJournal of Pharmaceutical and Biomedical Analysis
dc.subjectMeldoniumen
dc.subjectPharmacokineticsen
dc.subjectUrinary excretionen
dc.subjectDoping analysisen
dc.titleUrinary excretion studies of meldonium after multidose parenteral applicationen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractДикић, Ненад; Јанчић-Стојановић, Биљана; Форсдахл, Гуро; Геисендорфер, Томас; Јеитлер, Вероника; Aнђелковић, Марија; Гмеинер, Гунтер;
dc.citation.volume161
dc.citation.spage289
dc.citation.epage295
dc.citation.other161: 289-295
dc.citation.rankM21
dc.identifier.wos000447682300031
dc.identifier.doi10.1016/j.jpba.2018.08.053
dc.identifier.pmid30189410
dc.identifier.scopus2-s2.0-85052653931
dc.identifier.rcubconv_4236
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record